AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05451394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROAF
Description: Use of the method Ressource Optimisation of Armed Forces (ROAF). 6 one-hour workshops
Study NCT05451394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: 6 one-hour workshops on cognitive process
Study NCT05610475 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood cell analysis, blood gas surveillance, chest radiograph and echocardiography
Description: Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
Study NCT05610475 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: blood cell analysis, blood gas surveillance, chest radiograph and echocardiography
Description: Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
Study NCT03309514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intracerebral microinjections
Description: Stereotactic delivery of cell suspension into basal ganglia structures
Study NCT04819477 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fact box
Description: All physicians surveyed receive a fact box with numerical information on the benefits and harms of chest CT as a screening method.~In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot.
Study NCT06345222 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prolotherapy
Description: The Modified Prolotherapy technique was applied in the study and 0.5cc 5% Dextrose injection was applied per injection to the tendon entesis and/or tendon of the patient's non-rheumatic chronic, myoskeletal knee-induced, pain-inducing sensation. The follow-up period was determined as 1 month after the last injection. The ligaments to be injected within the scope of the research (context knee pain) were determined as Lateral Collateral Ligament (LCL), AnteroLateral Collateral Ligament (ALL), Medial Collateral Ligament (MCL), Pes Anserius and Patellar Ligament.
Study NCT06345222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: The Modified Prolotherapy technique was applied in the study and 0.5cc 5% Dextrose injection was applied per injection to the tendon entesis and/or tendon of the patient's non-rheumatic chronic, myoskeletal knee-induced, pain-inducing sensation. The follow-up period was determined as 1 month after the last injection. The ligaments to be injected within the scope of the research (context knee pain) were determined as Lateral Collateral Ligament (LCL), AnteroLateral Collateral Ligament (ALL), Medial Collateral Ligament (MCL), Pes Anserius and Patellar Ligament.
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H107e
Description: Participants will receive two i.m. injections of 20 µg unadjuvanted H107e on Day 1 and Day 29
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAF®10b
Description: Participants will receive two i.m. injections of CAF®10b (full adjuvant dose) on Day 1 and Day 29
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H107e/CAF®10b - low adjuvant dose
Description: Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (low adjuvant dose) on Day 1 and Day 29
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H107e/CAF®10b - full adjuvant dose
Description: Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose intranasal H107e
Description: Participants will receive one i.n. administration of 15 µg H107e (low dose intranasal H107e) on Day 85
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full dose intranasal H107e
Description: Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 85
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H107e/CAF®10b
Description: Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: i.m. placebo
Description: Participants will receive two i.m. injections of placebo on Day 1 and Day 29
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: i.m. placebo
Description: Participants will receive two i.m. injections of placebo on Day 1 and Day 29
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Participants will receive one i.d. injection of BCG on Day 1
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: Participants will receive one i.d. injection of BCG on Day 1
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: i.d. placebo
Description: Participants will receive one i.d. injection of placebo on Day 1
Study NCT04819477 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cates plot
Description: In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot.
Study NCT06364202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut Butter
Description: 2 tablespoons of peanut butter
Study NCT05086666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: In Phase 1b study, subjects will receive continuous twice daily dosing in 21-day cycles (no matter if missed doses or delays exist), with pre-set dose cohorts of 80 mg BID and 120 mg BID.~In Phase 2, subjects will receive continuous twice daily dosing in 21-day cycles with the RP2D or other doses as determined by the investigator and sponsor.
Study NCT05059925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured gym activities
Description: Planned and structured activities such as Strength training~* Dumbbell Exercises (1kg with 2 sets of 10 repetitions)~* Sit-ups (2 sets of 10 repetitions)~* Stair climbing, (2 sets of 10 stairs up and down)~* Squat (2 sets of 10 repetitions) Flexibility training • Tai chi (Peng. Lu, chi, an Tsai, lieh, chou, Kao (Hold each posture for 20 seconds)) • Pilates (Breathing., Shoulder bridge, Leg lifts (Hold each pose for 20 seconds)) • Stretching techniques (Neck stretch, Shoulder stretch, Side stretch Hold each stretch for 20 seconds)).
Study NCT05059925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional aerobic activities
Description: Activities performed such as~* Treadmill Time: 10 minutes Intensity: 60 to 80% of target heart rate~* Cycle ergometer Time: 10 minutes Intensity: 60 to 80% of target heart rate~* Elliptical exercises Time: 10 minutes Intensity: 60 to 80% of target heart rate
Study NCT05964010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Screening
Description: All consented youth age 12-17 years complete a patient-facing, well-validated digital screening tool, the CRAFFT (Knight et al., 2003), which assesses number of days during the past year, and then the past 3 months, during which various formulations of AOD were used. If youth report 0 days of AOD use, the tool asks whether they have ridden in a car whose driver was intoxicated; if this response is negative, they are categorized Low Risk. If youth report > 0 days of AOD use, the tool asks five additional questions assessing use risk and consequences; also, youth who report nicotine use in the past 30 days complete a nicotine dependence checklist (DiFranza et al., 2002). Screen data are then combined to sort youth into three risk categories: Riding Risk Only (no reported AOD use but indicated rode in car driven by intoxicated person), Distant Use (reported AOD use in past year but not past 3 months), or Recent Use (reported AOD use in past 3 months).
Study NCT05964010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Psychoeducation
Description: In the wait area, youth receive a tablet-delivered brief digital AOD education tutorial that includes advice to abstain from or reduce AOD use. The tutorial focuses on adolescent AOD prevalence rates and related behavioral symptoms; AOD use neurobiology and its relation to adolescent health; and common AOD impacts on developmental milestones (see Meredith et al., 2021). Psychoeducation for AOD has shown positive effects as both a universal and selective prevention strategy (Bröning et al., 2021; Das et al., 2016).
Study NCT05964010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Brief Negotiated Interview (BNI)
Description: In primary care (PC) office, youth and providers together complete a tablet-supported brief negotiated interview (BNI; see Beaton et al., 2016). The BNI is informed by AOD use data gathered during youth screening (O'Grady et al., 2015). The BNI focuses on (a) education about AOD disorders, including youth and family factors that impact AOD use; (b) user-tailored feedback comparing the given youth's AOD use and related problems to national norms, along with information on neurobiological effects and developmental impacts of frequent use (Harris et al., 2012); (c) motivational tools (e.g., reduction readiness rulers) and decisional balance exercises (weighing positive versus negative personal impacts of AOD use) tailored to the youth's use levels (Slavet et al., 2006; King et al., 2009); and (d) AOD reduction goal-setting interventions tailored to the youth's readiness to change AOD use (Walton et al., 2013).
Study NCT05964010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Referral to Treatment (RT)
Description: In primary care (PC) offices providers and youth discuss the value of attending counseling services to address AOD-related problems (Cucciare et al., 2015); counseling referral links that the PC site curates with local services; and the value of youth talking directly with caregivers about their AOD involvement as a first step toward support-seeking and behavior change (Gayes \& Steele, 2014). Providers directly recommend AOD counseling and facilitate a first appointment for youth who agree.
Study NCT05964010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Screening
Description: Screening procedures incorporate procedures for youth described for Standard Screening. They also incorporate two sources of caregiver-report data. First is an estimate of youth AOD use based on the Screening 2 Brief Intervention tool (Levy et al., 2016). Second is a 9-item checklist of youth mental health (MH) problems (Achenbach \& Rescorla, 2001). If both youth and caregiver report no AOD use or clinical-level MH problem, the family is categorized Low Risk. Otherwise, screen data are combined to sort families into three risk categories: Hidden SU Risk (youth reports AOD use in past year; caregiver reports no youth AOD use in past year), Named MH Risk (caregiver reports no youth AOD use in past year; caregiver reports clinical-level score for at least one youth MH domain), Named SU Risk (caregiver reports youth AOD use in past year).
Study NCT05964010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Psychoeducation
Description: Youth proceed as indicated in the SBIRT-A-Standard condition based on youth screen data. In the wait area, caregivers receive a tablet-delivered parenting tutorial that covers two AOD risk domains: education about adolescent AOD including prevalence rates, related behavior problems, neurobiological and health effects, and impacts on developmental milestones; and education and video modeling about parenting strategies that reduce or moderate AOD risk, including positive communication, fair and consistent discipline, and non-judgmental conversations about AOD use (Bo et al., 2018). Positive parenting education has been shown effective as a universal and selective prevention strategy in parent-focused AOD prevention trials (Kuntsche \& Kuntshce, 2016; Ladis et al., 2019; Van Ryzin et al., 2017). Tutorials are tailored for each risk category.
Study NCT05964010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Brief Negotiated Interview (BNI)
Description: Youth proceed as indicated in the SBIRT-A-Standard condition based on youth screen data. In primary care (PC) offices, caregivers and providers together complete a tablet-supported parenting BNI informed by data from the caregiver screen only that parallels the youth BNI (e.g., AOD education, developmental risks) and also includes motivation, modeling, and goal-setting on positive parenting (e.g., non-judgmental conversations; see above) and effective parent-youth communication about AOD use (Carver et al., 2017).
Study NCT05964010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Facilitated Conversation (FC) & Referral to Treatment (RT)
Description: In PC offices, providers meet separately with youth and caregivers to discuss the value of talking directly with the other family member about AOD risk while practicing positive communication strategies. Whenever both youth and caregiver agree to talk together, providers convene a brief facilitated conversation about AOD risk. In this conversation providers (a) emphasize that a positive youth-caregiver relationship is the strongest protective factor for youth development and (b) follow guidelines for brief triadic risk-reduction interventions focused on positive family communication about AOD risk (Guilamo-Ramos et al., 2020). When indicated, providers directly recommend AOD counseling and facilitate a first appointment for families who agree.
Study NCT05576428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and exercise
Description: diet and exercise in patients of NAFLD
Study NCT05576428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and exercise
Description: diet and exercise in patients of NAFLD
Study NCT05576428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAC with diet and exercise
Description: NAC with diet and exercise in patients of NAFLD
Study NCT05072587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based diet with no oxysterols
Description: This group will be given 3 prepared plant-based meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
Study NCT05072587 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard ADA Diet (SADA)
Description: This group will be given 3 prepared meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
Study NCT04783103 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil
Description: 3 weeks home use
Study NCT04783103 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil
Description: 3 weeks home use
Study NCT06319651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Limb Resistance Band Exercises
Description: * Extending thighs~* Closing thighs~* Opening thighs~* Bending thighs~* Bending ankles~* Ankle opening
Study NCT06319651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Phase 1 cardiac rehabilitation
Description: Routine Phase 1 cardiac rehabilitation only.
Study NCT06319651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Phase 1 cardiac rehabilitation
Description: Routine Phase 1 cardiac rehabilitation only.
Study NCT06302725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal self sampling detecting HPV
Description: IMIDs patients who are not up to date with CCS be included into the study to perform a vaginal self-screening (VSS) A positive VSS will be confirmed by a standard HPV test and management of the results of standard HPV test or VSS will be performed as planned following HAS guidelines. For women with a positive VSS, follow-up results (HPV test and cytology, biopsy, etc.) will be collected according to the usual procedures of the screening facility and in accordance with the recommendations of the Health authorities
Study NCT04912713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stress group
Description: This group will perform the MAST stress protocol
Study NCT04912713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: This group will perform the MAST control protocol
Study NCT06355856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNN.22.17.036
Description: Apply twice daily to the affected area and around it.
Study NCT06355856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10573048700
Description: Apply twice daily to the affected area and around it.
Study NCT05127928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Vitamin C and vitamin E
Description: Antioxidant supplementation
Study NCT05127928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration
Study NCT04714762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eMOM GDM application
Description: Participants in the intervention group will use the eMOM GDM -application one week/month.~eMOM GDM application includes:~* continuous glucose monitor (CGM, Medtronic)~* diet (digital food tracker) (min 3 days during one application week)~* heartrate, stress and physical activity with the wrist-worn activity tracker (Vivosmart 3)~* weight measured once a week~The sensors can be worn and the application used during the whole pregnancy (if a mother is interested in)
Study NCT04660773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NB UVB phototherapy
Description: ultraviolet phototherapy sessions
Study NCT04660773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: oral medication
Study NCT06621576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM2002 injection
Description: Eligible subjects under general anesthesia will undergo CABG surgery. After completing the distal anastomosis, 5mg of HM2002 injection solution drawn into a 1 ml syringe will be administered via multi-point injection using an OT needle or insulin needle (preferably a 30G needle). The injections will be spaced approximately 1 cm apart, with no more than 30 injection points, into the myocardium at the edge of the MI area (with obvious infarcts) or the area of the diseased coronary artery branches (without obvious infarcts) through the epicardium.
Study NCT06731725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DayDrop®
Description: The patient will administer 1 to 2 instillations each time it is necessary (at least 2 times a day) and will record it in their data collection notebook.
Study NCT06730152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeChat Intervention Based on the IMB Model
Description: The intervention group would undergo a six-week intervention program. Researchers promoted a public WeChat account to the intervention group, and participants received the intervention by following the account. They automatically received pushed articles or videos, providing them with relevant knowledge about overcoming smartphone addiction. Furthermore, they would be motivated to quit their addiction through real-life cases of smartphone addiction etc., in addition to some practical skills of overcoming.
Study NCT05698537 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EEG
Description: EEG registration performed in PwE to confirm epilepsy diagnosis
Study NCT05698537 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging
Description: Neuroimaging performed in PwE to diagnose epilepsy etiology
Study NCT05698537 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood samples from both PwE and controls will be collected to measure full blood count, IgM and IgG antibodies to parasitic antigens including Taenia solium, Toxoplasma gondii and Plasmodium falciparum, to perform ELISA for HIV1 and HIV2, to measure HIV viral load and to conduct an emmel test.
Study NCT05698537 — intervention group
Intervention type: OTHER
Intervention: Risk factor questionnaire
Description: Both PwE and control subjects will complete a structured questionnaire on a wide range of potential risk factors present before the onset of the epilepsy.
Study NCT05699876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 6 MG
Description: melatonin will be administered orally preoperatively as premedication
Study NCT05699876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: melatonin will be administered orally preoperatively as premedication
Study NCT05583045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive Leaf Tea
Description: Olive leaf tea (individual tea bags provided to participants with instructions of preparation)